Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Nephrol ; 16(6): 807-12, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14736007

RESUMO

BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients.


Assuntos
Anti-Hipertensivos/uso terapêutico , Arteriosclerose/terapia , Ácidos Heptanoicos/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Pirróis/uso terapêutico , Obstrução da Artéria Renal/terapia , Artéria Renal , Stents , Angioplastia com Balão , Arteriosclerose/complicações , Arteriosclerose/fisiopatologia , Atorvastatina , Terapia Combinada , Progressão da Doença , Humanos , Rim/fisiopatologia , Obstrução da Artéria Renal/etiologia , Obstrução da Artéria Renal/fisiopatologia , Projetos de Pesquisa
2.
Neth J Med ; 60(1): 29-32, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12074041

RESUMO

We report a 25-year-old woman presenting with a flaccid paresis due to severe hypokalaemia as a consequence of distal renal tubular acidosis (dRTA). Six years after presentation of dRTA, she developed overt symptoms of systemic lupus erythematosus (SLE). dRTA in SLE is often secondary to an interstitial nephritis. In contrast to other reports the dRTA did not resolve after treatment with prednisone in our patient. Nephrocalcinosis might be one of the causal factors in the persistence of dRTA.


Assuntos
Acidose Tubular Renal/etiologia , Lúpus Eritematoso Sistêmico/complicações , Nefrite Lúpica/complicações , Paralisia/etiologia , Acidose Tubular Renal/diagnóstico , Adulto , Feminino , Seguimentos , Humanos , Testes de Função Renal , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Nefrite Lúpica/diagnóstico , Nefrite Lúpica/tratamento farmacológico , Hipotonia Muscular , Paralisia/diagnóstico , Prednisona/administração & dosagem , Medição de Risco , Tomografia Computadorizada por Raios X , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA